Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems

Cell-penetrating peptides have gained attention owing to their promise in noninvasive delivery systems. Among the identified cell-penetrating peptides, the TAT peptide has been preferentially used for transduction into cells of diverse origins. However, this activity is nonselective between neoplastic and non-neoplastic cells. Here we describe artificial cell-penetrating peptides that are selectively and efficiently incorporated into human tumour cells, according to their lineage. Ten representative tumour lineage-homing cell-penetrating peptides were obtained by screening of a random peptide library constructed using messenger RNA display technology, and some of the isolates were further modified by amino-acid substitution. Their advantageous tumour cell-targeting ability is corroborated in an in vivo mouse model for imaging and growth suppression of metastatic xenoplant tumours. These cell-penetrating peptides are potentially useful for the efficient targeting of human neoplasms in a tumour origin-dependent manner, and provide a framework for the development of peptide-based anti-tumour technologies.

[1]  D. Mason,et al.  A new macrophage differentiation antigen which is a member of the scavenger receptor superfamily , 1993, European journal of immunology.

[2]  J. Herman,et al.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.

[3]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[4]  E. Campo,et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.

[5]  E. Campo,et al.  p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. , 1998, Blood.

[6]  R. Fåhraeus,et al.  Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule , 1998, Oncogene.

[7]  M. Kojiro,et al.  Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines , 1999, Hepatology.

[8]  R. Roberts.  Totally in vitro protein selection using mRNA-protein fusions and ribosome display. , 1999, Current opinion in chemical biology.

[9]  U. Holmskov,et al.  Cloning of a Novel Scavenger Receptor Cysteine-Rich Type I Transmembrane Molecule (M160) Expressed by Human Macrophages1 , 2000, The Journal of Immunology.

[10]  K. Pattabiraman,et al.  The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Fink,et al.  Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors. , 2001, Experimental hematology.

[12]  T. Yoshino,et al.  Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. , 2004, Molecular cancer therapeutics.

[13]  Steven F. Dowdy,et al.  Cell Penetrating Peptides in Drug Delivery , 2004, Pharmaceutical Research.

[14]  Jeremy C Simpson,et al.  Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Steven F Dowdy,et al.  Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. , 2005, Advanced drug delivery reviews.

[16]  W. Wels,et al.  Recombinant derivatives of the human high‐mobility group protein HMGB2 mediate efficient nonviral gene delivery , 2005, The FEBS journal.

[17]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[18]  T. Kirchhausen,et al.  Dynasore, a cell-permeable inhibitor of dynamin. , 2006, Developmental cell.

[19]  Y. Husimi,et al.  Solid-phase translation and RNA–protein fusion: a novel approach for folding quality control and direct immobilization of proteins using anchored mRNA , 2006, Nucleic acids research.

[20]  S. Dowdy,et al.  TAT transduction: the molecular mechanism and therapeutic prospects. , 2007, Trends in molecular medicine.

[21]  S. Futaki,et al.  Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. , 2007, Biochemistry.

[22]  Satyajit Mayor,et al.  Pathways of clathrin-independent endocytosis , 2007, Nature Reviews Molecular Cell Biology.

[23]  M. Morris,et al.  Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. , 2008, Advanced drug delivery reviews.

[24]  T. Yoshino,et al.  Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines , 2008, Molecular Cancer Therapeutics.

[25]  G. Núñez,et al.  Clathrin- and Dynamin-Dependent Endocytic Pathway Regulates Muramyl Dipeptide Internalization and NOD2 Activation1 , 2009, The Journal of Immunology.

[26]  A. Fukamizu,et al.  Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications. , 2009, International journal of molecular medicine.

[27]  H. Nemoto,et al.  Methylation of the p16 gene is frequently detected in lymphatic-invasive gastric cancer. , 2010, Anticancer research.

[28]  A. Harris,et al.  Delta-like ligand 4-notch blockade and tumor radiation response. , 2011, Journal of the National Cancer Institute.